Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer
Cervical cancer and its precursor lesion, cervical intraepithelial neoplasia (CIN), are caused by high-risk human papillomavirus (HPV) viral infection and are highly susceptible to host immunity targeting of HPV viral proteins, which include both foreign antigens and cancer antigens expressed by tum...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455923003005 |
| _version_ | 1797356986298269696 |
|---|---|
| author | Osamu Kobayashi Ayumi Taguchi Takahiro Nakajima Yuji Ikeda Keisuke Saito Kei Kawana |
| author_facet | Osamu Kobayashi Ayumi Taguchi Takahiro Nakajima Yuji Ikeda Keisuke Saito Kei Kawana |
| author_sort | Osamu Kobayashi |
| collection | DOAJ |
| description | Cervical cancer and its precursor lesion, cervical intraepithelial neoplasia (CIN), are caused by high-risk human papillomavirus (HPV) viral infection and are highly susceptible to host immunity targeting of HPV viral proteins, which include both foreign antigens and cancer antigens expressed by tumors. Immunotherapy that induces Th1 immunoreactivity against viral proteins is expected to take advantage of this immunological regression mechanism. However, although cancer immunotherapies for cervical cancer and CIN have been developed over the past several decades, none have been commercialized. Most of these immunotherapies target the viral cancer proteins E6 and E7, which are generally the same. The reasons for the underdevelopment of HPV-targeted immunotherapy differ depending on whether the target is invasive cancer or CIN. We here summarize the developmental history of cancer immunotherapy for CIN and discuss strategies for solving the problems that led to this underdevelopment. We note that CIN is a mucosal lesion and propose that inducing mucosal immunity may be the key. |
| first_indexed | 2024-03-08T14:36:47Z |
| format | Article |
| id | doaj.art-ec927081776b420a840bc5e8f90a5840 |
| institution | Directory Open Access Journal |
| issn | 1028-4559 |
| language | English |
| last_indexed | 2024-03-08T14:36:47Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj.art-ec927081776b420a840bc5e8f90a58402024-01-12T04:55:03ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592024-01-016312228Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancerOsamu Kobayashi0Ayumi Taguchi1Takahiro Nakajima2Yuji Ikeda3Keisuke Saito4Kei Kawana5Department of Obstetrics and Gynecology, Nihon University School of Medicine, JapanDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, JapanDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, JapanDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, JapanDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, JapanDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Japan; Corresponding author. 30-1 Oyaguchi-kamimachi, Itabashi-ku Tokyo, 173-8610, Japan.Cervical cancer and its precursor lesion, cervical intraepithelial neoplasia (CIN), are caused by high-risk human papillomavirus (HPV) viral infection and are highly susceptible to host immunity targeting of HPV viral proteins, which include both foreign antigens and cancer antigens expressed by tumors. Immunotherapy that induces Th1 immunoreactivity against viral proteins is expected to take advantage of this immunological regression mechanism. However, although cancer immunotherapies for cervical cancer and CIN have been developed over the past several decades, none have been commercialized. Most of these immunotherapies target the viral cancer proteins E6 and E7, which are generally the same. The reasons for the underdevelopment of HPV-targeted immunotherapy differ depending on whether the target is invasive cancer or CIN. We here summarize the developmental history of cancer immunotherapy for CIN and discuss strategies for solving the problems that led to this underdevelopment. We note that CIN is a mucosal lesion and propose that inducing mucosal immunity may be the key.http://www.sciencedirect.com/science/article/pii/S1028455923003005Therapeutic vaccineLactobacillus-based vaccineImmunotherapyMucosal immunityCervical intraepithelial neoplasia (CIN) |
| spellingShingle | Osamu Kobayashi Ayumi Taguchi Takahiro Nakajima Yuji Ikeda Keisuke Saito Kei Kawana Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer Taiwanese Journal of Obstetrics & Gynecology Therapeutic vaccine Lactobacillus-based vaccine Immunotherapy Mucosal immunity Cervical intraepithelial neoplasia (CIN) |
| title | Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer |
| title_full | Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer |
| title_fullStr | Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer |
| title_full_unstemmed | Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer |
| title_short | Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer |
| title_sort | immunotherapy that leverages hpv specific immune responses for precancer lesions of cervical cancer |
| topic | Therapeutic vaccine Lactobacillus-based vaccine Immunotherapy Mucosal immunity Cervical intraepithelial neoplasia (CIN) |
| url | http://www.sciencedirect.com/science/article/pii/S1028455923003005 |
| work_keys_str_mv | AT osamukobayashi immunotherapythatleverageshpvspecificimmuneresponsesforprecancerlesionsofcervicalcancer AT ayumitaguchi immunotherapythatleverageshpvspecificimmuneresponsesforprecancerlesionsofcervicalcancer AT takahironakajima immunotherapythatleverageshpvspecificimmuneresponsesforprecancerlesionsofcervicalcancer AT yujiikeda immunotherapythatleverageshpvspecificimmuneresponsesforprecancerlesionsofcervicalcancer AT keisukesaito immunotherapythatleverageshpvspecificimmuneresponsesforprecancerlesionsofcervicalcancer AT keikawana immunotherapythatleverageshpvspecificimmuneresponsesforprecancerlesionsofcervicalcancer |